JP5362549B2 - 呼吸器疾患の治療に有用な組成物及びキット - Google Patents
呼吸器疾患の治療に有用な組成物及びキット Download PDFInfo
- Publication number
- JP5362549B2 JP5362549B2 JP2009506029A JP2009506029A JP5362549B2 JP 5362549 B2 JP5362549 B2 JP 5362549B2 JP 2009506029 A JP2009506029 A JP 2009506029A JP 2009506029 A JP2009506029 A JP 2009506029A JP 5362549 B2 JP5362549 B2 JP 5362549B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically active
- kit
- weight
- aldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明の機器は、好ましくは組成物を含有する。本発明の機器の非限定例としては、瓶、キャニスター、容器、及び組み合わせが挙げられる。好ましくは、機器は透明である。透明な機器としては、ユーザーがその機器を通して組成物を見ることができる無色のもの及び有色のものの両方を挙げることができる。機器は、ある材料を含む。本発明に使用できる材料の非限定例としては、ポリエチレンテレフタレート(PET)、グリコール変性ポリエチレンテレフタレート(PETG)、配向ポリプロピレン(OPP)、ポリ塩化ビニル(PVC)、ポリ塩化ビニリデン(PVDC)、ナイロン、ポリエチレンテレフタレートポリエステル(PETP)、ポリフェン、及びこれらの組み合わせが挙げられる。好ましくは、本発明の材料はPETである。
本発明の機器は、好ましくは組成物を含有する。本発明の組成物は、本明細書に記載される材料で製造された機器中に置かれる場合に安定になる。本発明の組成物は、フェニレフリン、フェニレフリン遊離形態及び付加塩形態、並びにこれらの混合物を含む。フェニレフリンの非限定塩としては、塩酸フェニレフリン、及びフェニレフリン臭化水素酸塩が挙げられる。
本発明の組成物はまた、少なくとも1つの追加の医薬活性物質を含むことができる。医薬活性物質は、当業者が簡単に知ることのできるものであり、そのようなものとして、活性物質は、本明細書に与えられる説明に束縛されない。追加の医薬活性物質の非限定例としては、鎮咳剤、抗ヒスタミン剤、非鎮静性抗ヒスタミン剤、鬱血除去剤(decongestant)、去痰剤、鎮痛剤、解熱抗炎症剤、局所麻酔剤、抗炎症剤、鎮痛薬、薬草療法剤(herbal remedies)、ビタミン、栄養補助食品、酸化防止剤、天然成分、鉱物、エネルギー増強成分、睡眠補助薬、及び免疫系増強成分、及びこれらの混合物を挙げることができるが、これらに限定されない。
本発明の組成物は、甘さを提供するために、及び医薬活性物質(単数又は複数)の味をマスキングするのを助けるために、並びにある程度のコク(body)及び濃さ(thickness)を提供するために甘味剤を含んでもよい。甘味剤が本発明の組成物に存在する場合、組成物は、組成物の約0.0001重量%〜約30重量%の甘味剤、約0.0001重量%〜約20重量%の甘味剤、或いは約0.0001重量%〜約10重量%の甘味剤、約0.0001重量%〜約2重量%の甘味剤及び或いは約0.05重量%〜約1.0重量%の甘味剤を含んでもよい。本発明の甘味剤は、人工甘味剤及び/又は天然甘味剤であることができる。
呼吸器疾患及び症状の治療製品に通常関連する幾らか又は全ての構成成分は、必要に応じて、又は本明細書において追加成分として使用することができる。追加成分の非限定例には、溶媒、還元剤、塩化物塩、非アルデヒド系審美剤、冷却剤、着色剤、防腐剤、芳香剤、及びこれらの組み合わせが挙げられる。
本発明の組成物は、溶媒を含むことができる。1つの実施形態では、溶媒は、水溶性又は水混和性である。本明細書で使用する時、溶媒とは、フェニレフリン及び/又は他の医薬活性物質(単数又は複数)を溶解するために使用される物質を意味する。溶媒の非限定的な例は、水、プロピレングリコール、エタノール、グリセロール、ソルビトール、及びこれらの混合物から選択され得る。
本組成物は、所望によりキレート剤を含んでよい。微量の重金属イオンは、最終組成物の安定性を危うくし得る自動酸化反応に触媒作用を及ぼし得ることが見出された。
本組成物はまた、所望により還元剤を含んでもよい。還元剤を含むことは、本発明において使用される医薬活性物質に対して有益な化学的安定効果を及ぼし得る。したがって、本組成物において有用な還元剤は、選択された活性物質及びその溶解度に依存する。
本組成物は、所望により塩化物のような塩を含んでよく、これは、電位安定性効果を提供することが更に発見された。非限定的な例としては、塩化ナトリウム、塩化カリウム、塩化アンモニウム、及びこれらの混合物が挙げられる。
本発明の組成物はまた、任意に非アルデヒド系審美剤を含んでもよい。審美的に許容可能な組成物を提供するのが望ましい場合、本発明は更に、高濃度のアルデヒドを含有する通常の香味料及び香料に代わる選択肢を提供する。こうした選択肢は本明細書にて非アルデヒド系審美剤と呼ばれる。
更なる実施形態において、本発明は、本明細書に記載されるような組成物を治療が必要な哺乳類に経口投与することを含む呼吸器疾患を治療するための方法を対象とする。本明細書で使用する時、「呼吸器疾患」という用語は、広範囲の呼吸器の病気を包含し、それにはウィルス感染、例えばインフルエンザ及び一般的な風邪、並びにアレルギー、副鼻腔炎、鼻炎などが含まれる。更に本明細書で使用する時、呼吸器疾患に関する「治療」とは、言及した組成物の投与により、呼吸器疾患の1以上の症状又は呼吸器疾患自体を予防、軽減、改善、防止又は緩和するか、或いは治療が必要な哺乳類被検体、好ましくはヒトの呼吸器疾患に関するいずれかの同様の効果を意味する。
本発明はまたキットを含むことができる。本発明のキットは、機器中に含有される組成物を含むことができ、ここで前記組成物は、フェニレフリン、その遊離及び付加塩形態、並びにこれらの混合物からなる群から選択される医薬活性物質を含み、及び前記機器はポリエチレンテレフタレート(PET)、グリコール−変性ポリエチレンテレフタレート(PETG)、配向ポリプロピレン(OPP)、ポリ塩化ビニル(PVC)、ポリ塩化ビニリデン(PVDC)、ナイロン、ポリエチレンテレフタレートポリエステル(PETP)、ポリフェン、及びこれらの組み合わせからなる群から選択される材料を含む。
以下に本発明の組成物の種々の非限定例を示す。
米国ニュージャージー州デイトン(Dayton)のIFFから入手可能な香味料
米国ミズーリ州セントルイスのセンシエント・ファーマシューティカルズ・テクノロジー(Sensient Pharmaceuticals Tech)から入手可能な着色剤
Claims (16)
- 透明機器であって、機器中に含有される経口組成物を含み、前記組成物が、フェニレフリン塩酸塩である医薬活性物質を含み、前記組成物が、0.1重量%未満のアルデヒドを含み、及び前記機器の材料が、ポリエチレンテレフタレート(PET)であり、前記組成物が非アルデヒド系である、香味料及び香料から選択される審美剤を含み、前記組成物が、2〜5のpHを有し、前記組成物が、0.0001重量%〜2重量%の塩を含み、前記塩が、塩化ナトリウム、塩化カリウム、塩化アンモニウム、及びこれらの混合物からなる群から選択される、透明機器。
- 前記組成物が、0.0001mg〜60mgのフェニレフリンを含む、請求項1に記載の透明機器。
- 前記組成物が、アセトアミノフェン及び/又はデキストロメトルファンをさらに含む、請求項1又は2に記載の透明機器。
- 前記組成物の0.0001重量%〜60重量%の医薬活性物質を含む、請求項1〜3のいずれか一項に記載の透明機器。
- 前記組成物が甘味剤を更に含み、前記甘味剤が人工甘味剤を含み、前記人工甘味剤がサッカリンナトリウム、アセスルファムカリウム、スクラロース、アスパルテーム、グリチルリチン酸モノアンモニウム、ネオヘスペリジンジヒドロカルコン、タウマチン、ネオテーム、シクラメート、及びこれらの混合物からなる群から選択され、前記組成物が前記組成物の0.0001重量%〜1重量%の前記人工甘味剤を含む、請求項1〜4のいずれか一項に記載の透明機器。
- 前記組成物が少なくとも1つの追加の医薬活性物質を更に含み、前記追加の医薬活性物質が、鎮咳剤、抗ヒスタミン剤、非鎮静性抗ヒスタミン剤、鬱血除去剤、去痰剤、鎮痛剤、解熱抗炎症剤、局所麻酔剤、抗炎症剤、粘滑剤、薬草療法剤、ビタミン、栄養補助食品、酸化防止剤、天然成分、鉱物、エネルギー増強成分、睡眠補助薬、及び免疫系増強成分、及びこれらの混合物からなる群から選択される、請求項1〜5のいずれか一項に記載の透明機器。
- 前記組成物がキレート剤を更に含み、前記キレート剤がエチレンジアミン四酢酸(EDTA)、EDTA四ナトリウム、ヘキサメタリン酸ナトリウム(SHMP)、クエン酸、リン酸、ジ(ヒドロキシエチル)グリシン、8−ヒドロキシキノリン、これらの塩及びこれらの混合物からなる群から選択され、前記組成物が前記組成物の0.0001重量%〜2重量%の前記キレート剤を含む、請求項1〜6のいずれか一項に記載の透明機器。
- 前記組成物が、溶媒、還元剤、非アルデヒド系審美剤、塩化物塩、冷却剤、着色剤、防腐剤、芳香剤、及びこれらの組み合わせからなる群から選択される追加成分を更に含む、請求項1〜7のいずれか一項に記載の透明機器。
- 前記機器が一回用量あたり5mL〜50mLの前記組成物を送達する、請求項1〜8のいずれか一項に記載の透明機器。
- 前記組成物が1日あたり少なくとも1回投与される、請求項1〜9のいずれか一項に記載の透明機器。
- 機器に含有される経口組成物を含むキットであって、前記組成物が、フェニレフリン塩酸塩である医薬活性物質を含み、前記組成物が、0.1重量%未満のアルデヒドを含み、前記機器の材料が、ポリエチレンテレフタレート(PET)であり、前記組成物が非アルデヒド系である、香味料及び香料から選択される審美剤を含み、前記組成物が、2〜5のpHを有し、前記組成物が、0.0001重量%〜2重量%の塩を含み、前記塩が、塩化ナトリウム、塩化カリウム、塩化アンモニウム、及びこれらの混合物からなる群から選択される、キット。
- 前記組成物が、0.0001mg〜60mgのフェニレフリンを含む、請求項11に記載のキット。
- 前記組成物が、アセトアミノフェン及び/又はデキストロメトルファンをさらに含む、請求項11又は12に記載のキット。
- 一組の使用説明書を更に含む、請求項11〜13のいずれか一項に記載のキット。
- 前記組成物が少なくとも1つの追加の医薬活性物質を更に含む、請求項11〜14のいずれか一項に記載のキット。
- 前記キットが少なくとも1つの追加の医薬活性物質を更に含む、請求項11〜15のいずれか一項に記載のキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/408,299 US10022339B2 (en) | 2006-04-21 | 2006-04-21 | Compositions and methods useful for treatment of respiratory illness |
US11/408,299 | 2006-04-21 | ||
US11/657,860 US20070249727A1 (en) | 2006-04-21 | 2007-01-25 | Compositions and kits useful for treatment of respiratory illness |
US11/657,860 | 2007-01-25 | ||
PCT/IB2007/051470 WO2007122581A2 (en) | 2006-04-21 | 2007-04-20 | Compositions and kits of phenylephrine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009535305A JP2009535305A (ja) | 2009-10-01 |
JP5362549B2 true JP5362549B2 (ja) | 2013-12-11 |
Family
ID=48805455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009506029A Expired - Fee Related JP5362549B2 (ja) | 2006-04-21 | 2007-04-20 | 呼吸器疾患の治療に有用な組成物及びキット |
Country Status (11)
Country | Link |
---|---|
US (6) | US20070249727A1 (ja) |
EP (1) | EP2046289B1 (ja) |
JP (1) | JP5362549B2 (ja) |
CN (1) | CN101631539A (ja) |
AU (1) | AU2007242419B2 (ja) |
BR (1) | BRPI0710483B8 (ja) |
CA (1) | CA2650036C (ja) |
ES (1) | ES2454967T3 (ja) |
MX (1) | MX2008013257A (ja) |
PL (1) | PL2046289T3 (ja) |
WO (1) | WO2007122581A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
US20070254027A1 (en) * | 2006-04-28 | 2007-11-01 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
EP2437781B1 (en) * | 2009-06-04 | 2013-07-24 | Alk AG | Stabilised composition comprising at least one adrenergic compound |
US9101529B2 (en) * | 2009-10-12 | 2015-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
WO2011107150A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
ES2795291T3 (es) * | 2013-02-13 | 2020-11-23 | Procter & Gamble | Medicamento con sabor a anís |
WO2016024928A1 (en) * | 2014-08-14 | 2016-02-18 | Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Taste masked paracetamol formulations |
US11213480B1 (en) | 2015-08-06 | 2022-01-04 | Hikma Pharmaceuticals International Limited | Phenylephrine hydrochloride ready-to-use solution |
CN110809465B (zh) * | 2017-03-27 | 2022-10-25 | 帕拉卡普制药有限公司 | 含有祛痰剂或减充血剂的制剂 |
GR1009541B (el) * | 2018-02-26 | 2019-06-07 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. | Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν μελατονινη |
US11911517B2 (en) | 2018-05-16 | 2024-02-27 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
WO2023129926A1 (en) * | 2021-12-29 | 2023-07-06 | Baxter International Inc. | Phenylephrine premix formulations and uses thereof |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB836747A (en) | 1957-07-31 | 1960-06-09 | Upjohn Co | Improvements in or relating to steroidal compounds and compositions and the preparation thereof |
GB895495A (en) | 1960-01-20 | 1962-05-02 | Boots Pure Drug Co Ltd | Amino-acetamidoximes and their preparation |
US3169092A (en) | 1963-09-26 | 1965-02-09 | Richardson Merrell Inc | Stabilization of amines by tartrazine and bisulfite |
US3293045A (en) | 1963-10-18 | 1966-12-20 | Pfizer & Co C | Increasing the flavor strength of anethole, cinnamaldehyde and methyl salicylate with maltol |
GB1121358A (en) | 1965-10-21 | 1968-07-24 | Bristol Myers Co | Aerosol manufacture |
US3480185A (en) | 1966-06-20 | 1969-11-25 | Johnson & Johnson | Charged effervescing agent and medicament dispensing metering valve-actuated aerosol container producing a dose of medicament and carbonation in water |
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4049803A (en) | 1976-04-26 | 1977-09-20 | Bristol-Myers Company | Augmentation of blood levels of aspirin |
JPH0780760B2 (ja) * | 1986-07-28 | 1995-08-30 | ライオン株式会社 | 安定化されたフエニレフリン系液剤 |
EP0306469B1 (en) | 1987-09-04 | 1992-03-04 | The Procter & Gamble Company | Psyllium-containing filling compositions |
DK0387933T3 (da) | 1989-03-16 | 1993-12-06 | Procter & Gamble | Psylliumholdige, bagte småkagesammensætninger |
JP3256997B2 (ja) * | 1990-08-30 | 2002-02-18 | 千寿製薬株式会社 | 安定な水性製剤 |
US5178025A (en) | 1990-08-31 | 1993-01-12 | Innovative Medical Engineering, Inc. | Tiltable lift seat devices |
US5196436A (en) | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
US5296209A (en) | 1992-01-17 | 1994-03-22 | Colgate Palmolive Company | Pet chew product having oral care properties |
NZ256346A (en) * | 1992-10-09 | 1997-04-24 | Procter & Gamble | Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms |
US5480674A (en) | 1993-06-25 | 1996-01-02 | Firmenich Incorporated | Flavor composition for an oral electrolyte rehydration solution |
JP3643604B2 (ja) | 1993-09-17 | 2005-04-27 | セイコーインスツル株式会社 | 内面研削盤における研削方法 |
JP3021312B2 (ja) * | 1994-03-15 | 2000-03-15 | 千寿製薬株式会社 | プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤 |
GB9422571D0 (en) | 1994-11-09 | 1995-01-04 | Whitehall Lab Ltd | Haemorrihoidal compositions and method of use |
JPH09286726A (ja) | 1996-04-18 | 1997-11-04 | Takeda Chem Ind Ltd | 経口液剤 |
JPH09286723A (ja) | 1996-04-19 | 1997-11-04 | Takeda Chem Ind Ltd | 改善された経口液剤 |
JPH09286724A (ja) | 1996-04-19 | 1997-11-04 | Takeda Chem Ind Ltd | 経口用安定液剤 |
US5660833A (en) | 1996-06-05 | 1997-08-26 | Medenica; Rajko D. | Anti-tussive composition |
FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
JPH10167988A (ja) | 1996-10-09 | 1998-06-23 | Takeda Chem Ind Ltd | 経口液剤 |
US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
ATE241341T1 (de) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
PT1051155E (pt) | 1998-01-30 | 2002-10-31 | Novartis Consumer Health Sa | Solucoes nasais |
JP3262091B2 (ja) * | 1998-12-25 | 2002-03-04 | ライオン株式会社 | 洗眼剤組成物、洗眼剤組成物のべたつき感を解消する方法及び洗眼用セット |
US20020082307A1 (en) | 1999-01-11 | 2002-06-27 | Dobrozsi Douglas Joseph | Compositions having improved stability |
US6287597B1 (en) * | 1999-03-12 | 2001-09-11 | Carter-Wallace, Inc. | Antihistaminic/decongestant compositions |
US6218428B1 (en) * | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
WO2001087304A1 (fr) | 2000-05-17 | 2001-11-22 | Senju Pharmaceutical Co., Ltd. | Composition ophtalmique |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
AU2001291159A1 (en) * | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
JP2002212107A (ja) | 2001-01-22 | 2002-07-31 | Taisho Pharmaceut Co Ltd | 局所適用組成物 |
BR0211794A (pt) | 2001-07-31 | 2004-11-03 | Wyeth Corp | Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável |
US20030026826A1 (en) | 2001-07-31 | 2003-02-06 | Cherukuri Subraman Rao | Sugar-free chewy products and protein-based chewy products and methods for making the same |
JP2003063962A (ja) * | 2001-08-29 | 2003-03-05 | Taisho Pharmaceut Co Ltd | 鼻閉症用組成物 |
US20040132827A1 (en) * | 2001-10-26 | 2004-07-08 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
CA2466863A1 (en) * | 2001-11-29 | 2003-06-05 | Emisphere Technologies, Inc. | Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
US20030170371A1 (en) | 2002-01-10 | 2003-09-11 | Cargill, Inc. | High fat/fiber composition |
EP1471872A2 (en) * | 2002-02-04 | 2004-11-03 | Pharmacia Corporation | Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof |
EP1559433A4 (en) | 2002-10-22 | 2009-11-04 | Dainippon Sumitomo Pharma Co | STABILIZED COMPOSITION |
US20060193959A1 (en) | 2002-10-30 | 2006-08-31 | Li Nie | Low calorie injection molded starch-based pet chew bodies |
US20050214349A1 (en) | 2002-10-30 | 2005-09-29 | Li Nie | Extruded gluten based pet chew bodies |
US20040259955A1 (en) * | 2002-11-08 | 2004-12-23 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions containing ambroxol and isopropamide iodide |
DE10261061A1 (de) | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit |
JP2004217596A (ja) | 2003-01-17 | 2004-08-05 | Taisho Pharmaceut Co Ltd | 点眼剤組成物 |
US20040162273A1 (en) | 2003-01-23 | 2004-08-19 | The Procter & Gamble Company | Powder pharmaceutical compositions |
JP2004300138A (ja) | 2003-03-18 | 2004-10-28 | Takeda Chem Ind Ltd | 安定化された経口固形製剤 |
WO2004084637A1 (en) | 2003-03-24 | 2004-10-07 | Council Of Scientific And Industrial Research | A high fibre biscuit composition and a process for preparing the same |
JP4473539B2 (ja) | 2003-08-12 | 2010-06-02 | エスエス製薬株式会社 | 医薬組成物 |
US7118772B2 (en) | 2003-09-18 | 2006-10-10 | General Mills, Inc. | Inulin infused fruit and method of preparation |
DE10358213A1 (de) | 2003-12-12 | 2005-07-28 | Clariant Gmbh | Polyethylenglykol und dessen Herstellung |
US20050266032A1 (en) | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
JP2005247802A (ja) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | 点眼剤 |
US20050266031A1 (en) | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
WO2006022996A2 (en) | 2004-08-04 | 2006-03-02 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
US20060039973A1 (en) | 2004-08-19 | 2006-02-23 | Mary Aldritt | Effervescent composition including water soluble dietary fiber |
US20060148837A1 (en) * | 2005-01-04 | 2006-07-06 | Everett Laboratories, Inc. | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
US20060188450A1 (en) * | 2005-02-24 | 2006-08-24 | Tim Clarot | System and method for suppressing a cough |
DE102006030757A1 (de) | 2005-07-18 | 2007-02-01 | Carl Zeiss Smt Ag | Polarisationsoptimiertes Beleuchtungssystem |
US20070098785A1 (en) * | 2005-11-02 | 2007-05-03 | Tim Clarot | Medicant delivery system and device |
CA2636061C (en) | 2006-01-27 | 2015-06-02 | Cadbury Adams Usa Llc | Flavor-enhancing compositions, methods of manufacture, and methods of use |
US8940796B2 (en) | 2006-02-21 | 2015-01-27 | Wyeth Llc | Phenylephrine liquid formulations |
US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
US20070254027A1 (en) | 2006-04-28 | 2007-11-01 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
US20080014275A1 (en) | 2006-07-13 | 2008-01-17 | Buehler Gail K | Pharmaceutical suspensions and related methods |
US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
WO2008033155A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for prevention and treatment of rhinitis |
CN107811999A (zh) | 2013-02-04 | 2018-03-20 | Aft制药有限公司 | 包括苯肾上腺素和扑热息痛的组合药剂 |
-
2007
- 2007-01-25 US US11/657,860 patent/US20070249727A1/en not_active Abandoned
- 2007-04-20 JP JP2009506029A patent/JP5362549B2/ja not_active Expired - Fee Related
- 2007-04-20 EP EP07735602.0A patent/EP2046289B1/en not_active Revoked
- 2007-04-20 BR BRPI0710483A patent/BRPI0710483B8/pt not_active IP Right Cessation
- 2007-04-20 WO PCT/IB2007/051470 patent/WO2007122581A2/en active Application Filing
- 2007-04-20 CN CN200780014329A patent/CN101631539A/zh active Pending
- 2007-04-20 PL PL07735602T patent/PL2046289T3/pl unknown
- 2007-04-20 AU AU2007242419A patent/AU2007242419B2/en active Active
- 2007-04-20 ES ES07735602.0T patent/ES2454967T3/es active Active
- 2007-04-20 CA CA2650036A patent/CA2650036C/en not_active Expired - Fee Related
- 2007-04-20 MX MX2008013257A patent/MX2008013257A/es active IP Right Grant
-
2016
- 2016-12-20 US US15/384,369 patent/US10098873B2/en active Active
-
2018
- 2018-09-12 US US16/128,579 patent/US10688089B2/en active Active
-
2020
- 2020-05-13 US US15/930,540 patent/US11141415B2/en active Active
-
2021
- 2021-10-11 US US17/498,152 patent/US20220023236A1/en active Pending
-
2022
- 2022-02-01 US US17/590,796 patent/US11491151B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11491151B2 (en) | 2022-11-08 |
US10098873B2 (en) | 2018-10-16 |
AU2007242419B2 (en) | 2012-08-30 |
US20070249727A1 (en) | 2007-10-25 |
AU2007242419A1 (en) | 2007-11-01 |
MX2008013257A (es) | 2009-03-06 |
BRPI0710483A8 (pt) | 2018-01-02 |
EP2046289A2 (en) | 2009-04-15 |
US20200268746A1 (en) | 2020-08-27 |
WO2007122581A3 (en) | 2009-07-02 |
WO2007122581A2 (en) | 2007-11-01 |
US20220152016A1 (en) | 2022-05-19 |
US20220023236A1 (en) | 2022-01-27 |
EP2046289B1 (en) | 2014-01-29 |
CN101631539A (zh) | 2010-01-20 |
CA2650036A1 (en) | 2007-11-01 |
US20170100391A1 (en) | 2017-04-13 |
BRPI0710483B1 (pt) | 2019-07-30 |
PL2046289T3 (pl) | 2014-06-30 |
BRPI0710483B8 (pt) | 2021-05-25 |
US20190008851A1 (en) | 2019-01-10 |
US11141415B2 (en) | 2021-10-12 |
JP2009535305A (ja) | 2009-10-01 |
BRPI0710483A2 (pt) | 2011-08-16 |
CA2650036C (en) | 2012-10-23 |
ES2454967T3 (es) | 2014-04-14 |
US10688089B2 (en) | 2020-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5362549B2 (ja) | 呼吸器疾患の治療に有用な組成物及びキット | |
US11083697B2 (en) | Compositions and methods useful for treatment of respiratory illness | |
EP2012765B1 (en) | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness | |
AU2016219620B2 (en) | Compositions and methods useful for treatment of respiratory illness | |
AU2013206808B2 (en) | Compositions and methods useful for treatment of respiratory illness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120319 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120327 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120418 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121019 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130712 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130806 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130904 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |